Zomedica Issuance Of Capital Stock from 2010 to 2024

ZOM Stock  USD 0.13  0.00  0.00%   
Zomedica Pharmaceuticals Issuance Of Capital Stock yearly trend continues to be very stable with very little volatility. Issuance Of Capital Stock is likely to drop to 0.00. During the period from 2010 to 2024, Zomedica Pharmaceuticals Issuance Of Capital Stock quarterly data regression pattern had sample variance of 2447.3 T and median of  15,000,000. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
49.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Zomedica Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zomedica Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 183.8 K, Selling General Administrative of 30.5 M or Other Operating Expenses of 59.6 M, as well as many indicators such as Price To Sales Ratio of 7.4, Dividend Yield of 0.0 or PTB Ratio of 0.78. Zomedica financial statements analysis is a perfect complement when working with Zomedica Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Zomedica Pharmaceuticals Correlation against competitors.

Latest Zomedica Pharmaceuticals' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Zomedica Pharmaceuticals Corp over the last few years. It is Zomedica Pharmaceuticals' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zomedica Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Pretty Stable
   Issuance Of Capital Stock   
       Timeline  

Zomedica Issuance Of Capital Stock Regression Statistics

Arithmetic Mean27,068,086
Geometric Mean0.00
Coefficient Of Variation182.76
Mean Deviation26,918,015
Median15,000,000
Standard Deviation49,469,931
Sample Variance2447.3T
Range199.5M
R-Value0.19
Mean Square Error2539.1T
R-Squared0.04
Significance0.49
Slope2,116,389
Total Sum of Squares34261.8T

Zomedica Issuance Of Capital Stock History

2022null
2021199.5 M
202056.5 M

About Zomedica Pharmaceuticals Financial Statements

Zomedica Pharmaceuticals investors utilize fundamental indicators, such as Issuance Of Capital Stock, to predict how Zomedica Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:
Check out the analysis of Zomedica Pharmaceuticals Correlation against competitors.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.06)
Revenue Per Share
0.027
Quarterly Revenue Growth
0.018
Return On Assets
(0.09)
Return On Equity
(0.24)
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.